REFERENCES
- Bugat R, Suc E, Rougier PH et al. CPT-11 (Irinotecan) as second line therapy in advanced colorectal cancer: prelimi-nary results of a multicentric phase II study. Proc Am Soc Chin Oncol 1994; 13: 586.
- Slevin ML, Clark PI, Joel SP et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Chin Oncol 1989; 7: 1330–40.
- Hainsworth JD, Johnson DH, Fraizer SR, Greco FA Chronic daily administration of oral etoposide. A phase I Trial. J Chin Oncol 1989; 7: 396–401.
- Muggia FM, Selawry OS, Hansen HH. Clinical studies with a new podophyllotoxin derivative,epipodophyllotoxin, 4'-demethyl 9 (4,6 0 2 thenylidene-β-D-glucopyrano- side) (NSC-122819). Cancer Chemother Rep 1971; 55: 575–581.
- Bonadonna G, Viviani S, Valagussa P et al. Third-line salvage chemotherapy in Hodgkin's disease. Semin Oncol. 1985; 12: 23–25.
- Mathew P, Ribeiro RC, Sonnichsen D et al. Phase I study of oral etoposide in children with refractory solid tumors. J Chin Oncol 1994; 12: 1452–7.
- World Health Organization. WHO handbook for repor-ting results for cancer treatment, WHO offset publication no. 48, Geneva, World Health Organization, 1979.
- Hainsworth JD, Johnson DH, Greco FA. Chronic Etoposide schedules in the treatment of Non-Hodgkin's Lymphoma. Sem in Oncol 1992; 19 ( supp114): 1-7.
- Nichols CR. The role of etoposide therapy in germ cell cancer. Sem in Oncol 1992; 19 (Suppl 13): 72–77.
- Carney DN, Keane M, Grogan L. Oral etoposide in small cell lung cancer. Semin Oncol 1992; (Suppl 14): 40-44.
- Cavalli F, Zucchetti M, Gentili D et al. Phase I and cli-nical pharmacological evaluation of daily oral etoposide (VP-16). Proc Am Soc Clin Oncol 1992; 11: 257.